Azienda Socio Sanitaria Territoriale Rhodense
- Address
- Corso Europa 250, 20017 Rho, Italy
Digestive System Diseases
At Azienda Socio Sanitaria Territoriale Rhodense, the gastroenterology and digestive endoscopy team is running studies focused on digestive system diseases, especially Crohn’s disease and ulcerative colitis. This research is largely aimed at testing new treatments, improving long-term disease control, and better understanding healing in the bowel.
- Moderately to severely active Crohn’s disease
- Fistulizing perianal Crohn’s disease
- Ulcerative colitis, including severely active forms
- Studies of transmural healing and treatment response
The site is contributing to research on both symptom relief and deeper disease healing, with a strong emphasis on evaluating whether newer therapies can improve outcomes for people living with chronic inflammatory bowel conditions.
Immune System Diseases
Clinical trials at this hospital/clinic also cover immune system diseases, reflecting the role of inflammation-driven illness in the site’s research profile. Most of this work centers on inflammatory bowel disease, where investigators are assessing treatments that may help control immune-related inflammation more effectively over time.
- Crohn’s disease and related inflammatory conditions
- Ulcerative colitis with moderate to severe activity
- Long-term safety and maintenance of response
- Research on improving disease remission and durability of benefit
The research portfolio includes efforts to compare therapies, maintain remission, and support safer long-term management for patients with chronic immune-mediated digestive disorders.
Neoplasms
The site also participates in oncology studies within the neoplasms area, with trials addressing ovarian cancer and metastatic colorectal cancer. These studies are designed to evaluate treatment effectiveness, extend disease control, and explore better options for patients whose cancers have returned or are difficult to treat.
- Recurrent ovarian cancer
- BRCA wild-type advanced ovarian, fallopian tube, and primary peritoneal cancer
- Metastatic colorectal cancer in first-line treatment settings
- Maintenance treatment and progression-free survival outcomes
This oncology research at Azienda Socio Sanitaria Territoriale Rhodense focuses on whether new or combined treatment approaches can improve cancer control and support longer-lasting benefit after initial therapy.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Eli Lilly & Co.3active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eli Lilly & Co.4trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Socio Sanitaria Territoriale Rhodense
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Ulcerative Colitis | Merck Sharp & Dohme LLC | Phase III | Not Recruiting | Aug 2024 | — |
IMP list
lock Showing 1 of 12 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Mirikizumab | 3 | Unknown | 2018-09-13 | 2026-06-08 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.